FM
CRNX icon

Frazier Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Frazier Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,384,293
Closed -$39.3M – 11
2021
Q4 		$39.3M Buy
1,384,293
+532,987
+63% +$13.1M 3.03% 10
2021
Q3 		$17.9M Buy
+851,306
New +$17.8M 1.43% 22

Other funds holding CRNX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Frazier Management's CRNX Position: Q1 2022 in Review

Frazier Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2022, closing a stake of 1,384,293 shares — an estimated $39.3M sold.

Frazier Management first reported a position in CRNX in Q3 2021 and held it in 2 quarters. The position peaked at $39.3M in Q4 2021. 117 funds tracked by Wall St. Rank hold CRNX as of Q1 2022.

  • Frazier Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 1,384,293 Crinetics Pharmaceuticals shares in Q1 2022, an estimated $39.3M.
  • Frazier Management first reported a position in Crinetics Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Frazier Management's Crinetics Pharmaceuticals position peaked at $39.3M in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.